DOP002:Vedolizumab treatment persistence up to 3 years: Post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS studyECCO'18 Vienna 2018
1
DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn's Disease patients: A real world belgian cohort studyECCO'18 Vienna 2018
1
DOP004: Long-term safety of adalimumab in patients with Moderate to Severe Ulcerative Colitis: Interim results of a non-interventional registry, LEGACYECCO'18 Vienna 2018
1
DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonistsECCO'18 Vienna 2018
1
DOP006: A multicentre cohort study to assess the safety of vedolizumab for Inflammatory Bowel DiseaseECCO'18 Vienna 2018
1
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha resistant Inflammatory Bowel DiseaseECCO'18 Vienna 2018
1
DOP008: Safety of adalimumab in children and adolescents with Moderate to Severe Crohn’s Disease: Interim results of the CAPE registryECCO'18 Vienna 2018
1
DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for Inflammatory Bowel Disease: A multicentre consortium propensity score–matched analysisECCO'18 Vienna 2018
1
DOP011: Genotype-Phenotype association analysis of Inflammatory Bowel Disease in 6,395 East Asian subjects: Results from the international IBD Genetics ConsortiumECCO'18 Vienna 2018
1
DOP012: Disease demarcation in Ulcerative Colitis is associated with different patterns of gene expressionECCO'18 Vienna 2018
1
DOP013: An IBD associated variant in PTPN2 promotes inflammatory responses but enhances the anti-inflammatory effect of spermidineECCO'18 Vienna 2018
1
DOP014: Impact of genetic variation on gene and protein expression in Crohn’s DiseaseECCO'18 Vienna 2018
1
DOP015: Dysregulation of cell-type specific long ncRNA in the ileum of treatment naïve early onset Crohn DiseaseECCO'18 Vienna 2018
1
DOP016: Metagenomic analysis of intestinal mucosa revealed an IBD-specific shift in the eukaryotic gut virome composition at early stages of gut inflammationECCO'18 Vienna 2018
1
DOP017: Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn's DiseaseECCO'18 Vienna 2018
1
DOP018: Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn’s DiseaseECCO'18 Vienna 2018
1
DOP019: Immunomodulators reduce the risk of surgery and hospitalization in Crohn’s Disease in a prospective European population-based inception cohort – the Epi-IBD cohortECCO'18 Vienna 2018
1
DOP020:Thiopurine monotherapy still has a place in the treatment of patients with Mild-to-Moderate Crohn’s Disease in the biological eraECCO'18 Vienna 2018
1